Revvity
Yves Dubaquie has extensive work experience in the field of diagnostics and pharmaceuticals. Yves is currently working at Revvity as SVP Diagnostics since May 2023. Prior to that, they held the same role at PerkinElmer, Inc. from April 2022 to May 2023. Before that, they were SVP, Head of Diagnostics Solutions at MilliporeSigma from August 2019 to April 2022. Additionally, they served as the Global Head of Business Development at MilliporeSigma from January 2017 to July 2019. Yves also has experience in business development and licensing at Novartis Molecular Diagnostics from August 2009 to August 2012. Earlier in their career, they held various roles in business development at Ironwood Pharmaceuticals, Bristol-Myers Squibb Medical Imaging, and Bristol-Myers Squibb Pharmaceuticals. Yves started their career as a Postdoctoral Fellow at Genentech.
Yves Dubaquie obtained a Ph.D. in Biochemistry from the University of Basel from 1993 to 1997. Prior to that, they completed their Masters in Natural Sciences at ETH Zürich from 1988 to 1993. Yves Dubaquie also holds a Ph.D. certification from Universität Basel.
Revvity
8 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com